Powered by HumanexaHumanexa Review

Editorial intelligence for pharma strategy

AnalysisResearchOpinionCalendarNewsletterAbout
Pharma StrategyDrug DevelopmentCompetitive IntelligenceAI & HealthcareBiotech BusinessIndustry Analysis

Humanexa Review

Independent editorial analysis on pharma strategy, drug development, and market structure in life sciences.

Powered by Humanexa

AboutStudioNewsletterCalendar
Explore Humanexa Intelligence Platform

Editorial publication

Analysis for pharma strategy and market structure

Independent analysis on pharma strategy, drug development, competitive intelligence, and biotech business.

Featured

Industry Analysis·Jun 29, 2026·1 min read

Royalty Financing vs Equity for Late-Stage Assets

Non-dilutive capital structures are reshaping how pharma funds Phase 3 programs and launch preparation.

Humanexa Research

Drug Development·Jun 26, 2026·1 min read

Adaptive Trials Are Becoming the Default, Not the Exception

FDA guidance and sponsor experience data suggest adaptive designs will dominate oncology and rare disease programs.

Humanexa Research

Latest

Biotech Business·Jun 22, 2026·1 min read

In-Licensing Economics in a Higher-Cost-of-Capital Cycle

Rising cost of capital is compressing in-licensing valuations and shifting deal structures toward milestones, royalties, and staged proof points.

Humanexa Research

Newsletter

Weekly editorial intelligence

Curated analysis on pharma strategy, development, and competitive dynamics. No noise — just the signals that matter.

Contact review@humanexa.io for editorial inquiries.